Mareike Kristina Koerber

Dr. Mareike Kristina Koerber


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2013 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
PDF file
MKMareike Kristina Koerber
Mareike Kristina Koerber
ELElisabeth Langer
Elisabeth Langer
SZSabine Ziemer
Sabine Ziemer
EPElisabeth Perzborn
Elisabeth Perzborn
CGChristine Gericke
Christine Gericke
CHChristian von Heymann
Christian von Heymann
Background: Rivaroxaban (Xarelto, Bayer HealthCare, Leverkusen, Germany) is a new oral anticoagulant drug. Anticoagulants may cause bleeding, thereby requiring reliable monitoring and efficient therapy. We investigated thromboelastometry versus routine coagulation tests to measure prophylactic and therapeutic concentrations of rivaroxaban and their reversal with prothrombin complex concentrate (PCC) and activated recombinant factor VII (rFVIIa) in vitro. Methods: Rivaroxaban was solubilized, and PCC and rFVIIa were added in 2 concentrations to the rivaroxaban-spiked blood samples, and thromboelastometry and measurements were performed. Results: Rivaroxaban increased tissue factor–activated clotting time (CTExTEM) dose dependently. Activated partial prothrombin time (aPTT), prothrombin time ratio (PTR), and prothrombin time (PT) were changed significantly in both concentrations. Reversal with PCC in both dosages caused no significant change in the measured parameters. For prophylactic rivaroxaban dosage, rFVIIa changed the PT significantly but not CTExTEM, aPTT, and PTR. For therapeutic rivaroxaban dosage, the CTExTEM was significantly reduced. The other parameters remained unaffected. Conclusions: Thromboelastometry can detect rivaroxaban effects. In vitro rFVIIa seems highly effective for reversal in contrast to PCC.

27 March 2017 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Open access
PDF file
MKMareike Kristina Koerber
Mareike Kristina Koerber
ELElisabeth Langer
Elisabeth Langer
MKMartin Köhr
Martin Köhr
KWKlaus-Dieter Wernecke
Klaus-Dieter Wernecke
WKWolfgang Korte
Wolfgang Korte
CHChristian von Heymann
Christian von Heymann
Background: An increasing number of oral anticoagulants has been approved, including dabigatran etexilate (DE). DE is a direct thrombin inhibitor that requires no routine monitoring, but, if necessary (e.g. urgent surgery etc.), the diluted thrombin time measured with Hemoclot® has shown reliable results. So far, no point-of-care (PoC) assay is available to measure DE effects. The EcaTEM assay uses ecarin to initiate the coagulation cascade at the step of thrombin generation and measures the clotting time (CT) by thromboelastometry. Methods: This study investigated the correlation of the EcaTEM with standard laboratory assays in dabigatran-treated patients. Ten patients undergoing total hip or knee arthroplasty were included in the study. DE for thromboprophylaxis was started 4 h after surgery. Blood samples were taken before surgery as well as 2, 6 and 12 h after ingestion on the 3rd postoperative day. Dabigatran concentration (Hemoclot), activated partial thromboplastin time, thrombin time and CT EcaTEM were measured. Results: Only CT EcaTEM and Hemoclot showed a correlation > 0.75 for all measurements. Conclusion: CT EcaTEM appears a valid PoC method parameter to detect thrombin inhibition and thus the presence of dabigatran beside diluted thrombin time at different concentration levels. This may represent an opportunity to identify the presence of dabigatran, e.g., in emergency situations.

1 January 2016
Verified
Journal Article
Closed access
MKMareike Kristina Koerber
Mareike Kristina Koerber
ELElisabeth Langer
Elisabeth Langer
LKLutz Kaufner
Lutz Kaufner
MSMichael Sander
Michael Sander
CHChristian Von Heymann
Christian Von Heymann

19 June 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MKMareike Kristina Koerber
Mareike Kristina Koerber
SASarah Agaoglu
Sarah Agaoglu
ABAnna Bichmann
Anna Bichmann
Sascha TafelskiSascha Tafelski
Sascha Tafelski
INIrit Nachtigall
Irit Nachtigall
Background and Objectives: The impact of sex on mortality in patients with pneumonia requiring intensive care unit (ICU) treatment is still a controversial discussion, with studies providing heterogeneous results. The reasons for sex differences are widespread, including hormonal, immunologic and therapeutic approaches. This study’s aim was to evaluate sex-related differences in the mortality of ICU patients with pneumonia. Material and Methods: A prospective observational clinical trial was performed at Charité University Hospital in Berlin. Inclusion criteria were a diagnosis of pneumonia and a treatment period of over 24 h on ICU. A total of 436 mainly postoperative patients were included. Results: Out of 436 patients, 166 (38.1%) were female and 270 (61.9%) were male. Significant differences in their SOFA scores on admission, presence of immunosuppression and diagnosed cardiovascular disease were observed. Male patients were administered more types of antibiotics per day (p = 0.028) at significantly higher daily costs (in Euros) per applied anti-infective drug (p = 0.003). Mortalities on ICU were 34 (20.5%) in females and 39 (14.4%) in males (p = 0.113), before correcting for differences in patient characteristics using logistic regression analysis, and afterwards, the female sex showed an increased risk of ICU mortality with an OR of 1.775 (1.029–3.062, p = 0.039). Conclusions: ICU mortality was significantly higher in female patients with pneumonia. The identification of sex-specific differences is important to increase awareness among clinicians and allow resource allocation. The impact of sex on illness severity, sex differences in infectious diseases and the consequences on treatment need to be elucidated in the future.

1 March 2019
Verified
Journal Article
Closed access
KSKatrin Schmidt
Katrin Schmidt
KKKerstin Kruger
Kerstin Kruger
ELElisabeth Langer
Elisabeth Langer
MSMartin Schmutzler
Martin Schmutzler
EJElke Johnen
Elke Johnen
MKMareike Kristina Koerber
Mareike Kristina Koerber